"From evidence to practice" - Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services

被引：1

作者：

Brown, Adrian ^{[1
,2
,3
]}

Mellor, Duane ^{[4
,5
]}

Makaronidis, Janine ^{[1
,2
,6
]}

Shuttlewood, Emma ^{[7
]}

Miras, Alexander Dimitri ^{[8
]}

Pournaras, Dimitri J. ^{[9
]}

机构：

[1] UCL, Ctr Obes Res, London, England

[2] Univ Coll London Hosp NHS Trust, Bariatr Ctr Weight Management & Metab Surg, London, England

[3] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth & Care Res, London, England

[4] Univ Hosp Leicester NHS Trust, Nutr & Dietet, Leicester, England

[5] Aston Univ, Aston Med Sch, Birmingham, England

[6] Barts Hlth NHS Trust, Royal London Hosp, Dept Diabet & Metab, London, England

[7] Univ Hosp Coventry & Warwickshire NHS Trust, Specialist Weight Management Serv, Coventry, England

[8] Ulster Univ, Sch Nursing, Derry, North Ireland

[9] North Bristol Natl Hlth Serv Trust, Dept Bariatr & Metab Surg, Bristol, England

来源：

NUTRITION BULLETIN | 2024年 / 49卷 / 03期

关键词：

WEIGHT-LOSS MAINTENANCE; DOUBLE-BLIND; 3.0; MG; LIRAGLUTIDE; EFFICACY; PLACEBO; SAFETY; REGAIN; TRIAL;

D O I：

10.1111/nbu.12700

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

引用

页码：257 / 263

页数：7

共 50 条

[1] Newer GLP-1 receptor agonists and obesity-diabetes [J].

Brown, Emily ;

Cuthbertson, Daniel J. ;

Wilding, John P. .

PEPTIDES, 2018, 100 :61-67

[2] Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists [J].

Goldenberg, Ronald M. ;

Gilbert, Jeremy D. ;

Manjoo, Priya ;

Pedersen, Sue D. ;

Woo, Vincent C. ;

Lovshin, Julie A. .

OBESITY REVIEWS, 2024, 25 (03)

[3] GLP-1 receptor agonists in the treatment of obesity [J].

Disse, E. .

CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2024, 28 (01) :18-21

[4] Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis [J].

Ebrahimi, Pouya ;

Batlle, Juan Carlos ;

Ayati, Aryan ;

Maqsood, M. Haisum ;

Long, Clarine ;

Tarabanis, Constantine ;

Mcgowan, Natalie ;

Liebers, David T. ;

Laynor, Gregory ;

Hosseini, Kaveh ;

Heffron, Sean P. .

JAMA PSYCHIATRY, 2025,

[5] Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management [J].

Delrue, Charlotte ;

Speeckaert, Marijn M. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)

[6] Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier? [J].

Strong, Jennifer ;

Driscoll, Marcia S. .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2025, 26 (02) :175-182

[7] Obesity and prediabetes. Treatment using GLP-1 receptor agonists [J].

Ritzel, R. A. .

DIABETOLOGE, 2017, 13 (07) :482-486

[8] Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice COMMENT [J].

Wharton, Sean ;

Davies, Melanie ;

Dicker, Dror ;

Lingvay, Ildiko ;

Mosenzon, Ofri ;

Rubino, Domenica M. ;

Pedersen, Sue D. .

POSTGRADUATE MEDICINE, 2022, 134 (01) :14-19

[9] Emerging role of GLP-1 receptor agonists in the treatment of obesity [J].

Neff, Lisa M. ;

Kushner, Robert F. .

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 :263-273

[10] Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus [J].

Lahey, Alexa M. ;

Duprey, Karolyn ;

Montague, Riley C. ;

Schadler, Aric D. ;

Naseman, Kristina W. .

PHARMACOTHERAPY, 2025, :220-226

← 1 2 3 4 5 →